Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2009

01-04-2009 | Original Article

Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines

Authors: Scott M. Stoeger, Kenneth H. Cowan

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2009

Login to get access

Abstract

Previous studies have indicated that the ERK1/2 MAP kinase signaling pathway plays an important role not only in cell growth, cell cycle regulation, and differentiation, but also in determining the sensitivity of cells to anticancer agents as well. Furthermore, expression of kinase suppressor of Ras-1 (KSR1), a molecular scaffold that modulates signaling through the ERK1/2 MAP kinase pathway, has been shown to influence the cellular sensitivity to the anticancer agent cisplatin. To further define the role of KSR1 expression on drug sensitivity, the expression of KSR1 was examined in the NCI60 anticancer drug screen, a panel of cancer cell lines representing nine tissue types, established by the Developmental Therapeutics Program (DTP) at the National Cancer Institute (NCI). The expression of thousands of molecular targets has been examined in the NCI60 panel as well as the cellular toxicity for greater than 400,000 compounds. KSR1 expression varied almost 30-fold difference between the highest and lowest expressing cell lines in the NCI60. Using the COMPARE analysis algorithm, KSR1 expression was correlated with sensitivity of the compounds screened by DTP and several novel agents were identified whose sensitivity correlated with KSR1 expression in the NCI60 panel. Cytotoxicity of two agents, cytochalasin H and tunicamycin, identified through the COMPARE analysis of KSR1 expression and drug sensitivity, was also examined in wild type (KSR+/+) mouse embryo fibroblasts (MEFs) and MEFs deficient in KSR1 expression (KSR1−/−). These studies demonstrated enhanced sensitivity, as well as increased ERK activation, in KSR−/− MEFs following exposure to tunicamycin or cytochalasin H compared to KSR+/+ MEFs. Furthermore, restoration of KSR1 expression in KSR−/− MEFs following stable transduction of cells with a KSR1 expression vector, enhanced sensitivity of cells to tunicamycin and cytochalasin H and decreased ERK1/2 activation following exposure to these drugs. In addition, the sensitivity to cytochalasin H and tunicamycin of breast cancer cell lines with low KSR1 expression, (HS578T and MDA-MB-231/ATCC), was increased relative to the sensitivity of breast cancer cells with higher levels of KSR1 (MCF7). These studies indicate that KSR1 may play an important role in the determination of cellular sensitivity to anticancer agents.
Literature
1.
Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L et al (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599–605PubMed
2.
Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T (1995) Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 95:2205–2214PubMedCrossRef
3.
Berton G, Fumagalli L, Laudanna C, Sorio C (1994) Beta 2 integrin-dependent protein tyrosine phosphorylation and activation of the FGR protein tyrosine kinase in human neutrophils. J Cell Biol 126:1111–1121PubMedCrossRef
4.
Boyd MR (2004) The NCI human tumor cell line (60-cell) screen: concept, implementation, and applications. In: Teicher B, Monks AP (eds) Anticancer drug development guide. Humana Press, Totowa, pp 41–61
5.
Burt RK, Garfield S, Johnson K, Thorgeirsson SS (1988) Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals. Carcinogenesis 9:2329–2332PubMedCrossRef
6.
Cacace AM, Michaud NR, Therrien M, Mathes K, Copeland T, Rubin GM, Morrison DK (1999) Identification of constitutive and ras-inducible phosphorylation sites of KSR: implications for 14-3-3 binding, mitogen-activated protein kinase binding, and KSR overexpression. Mol Cell Biol 19:229–240PubMed
7.
Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973–2978PubMed
8.
Continolo S, Baruzzi A, Majeed M, Caveggion E, Fumagalli L, Lowell CA, Berton G (2005) The proto-oncogene Fgr regulates cell migration and this requires its plasma membrane localization. Exp Cell Res 302:253–269PubMedCrossRef
9.
Dickstein B, Valverius EM, Wosikowski K, Saceda M, Pearson JW, Martin MB, Bates SE (1993) Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J Cell Physiol 157:110–118PubMedCrossRef
10.
Dickstein BM, Wosikowski K, Bates SE (1995) Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 110:205–211PubMedCrossRef
11.
Gee JM, Robertson JF, Ellis IO, Nicholson RI (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95:247–254PubMedCrossRef
12.
Gerlier D, Thomasset N (1986) Use of MTT colorimetric assay to measure cell activation. J Immunol Methods 94:57–63PubMedCrossRef
13.
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R et al (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) breast cancer study group. J Clin Oncol 10:1049–1056PubMed
14.
Hagan MP, Yacoub A, Dent P (2007) Radiation-induced PARP activation is enhanced through EGFR-ERK signaling. J Cell Biochem 12:12
15.
Hu P, Han Z, Couvillon AD, Exton JH (2004) Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J Biol Chem 279:49420–49429 (Epub 2004 Aug 31)PubMedCrossRef
16.
17.
Hung CC, Ichimura T, Stevens JL, Bonventre JV (2003) Protection of renal epithelial cells against oxidative injury by endoplasmic reticulum stress preconditioning is mediated by ERK1/2 activation. J Biol Chem 278:29317–29326 (Epub May 8 2003)PubMedCrossRef
18.
Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA, Zhang XD, Hersey P (2007) Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Cancer Res 67:9750–9761PubMedCrossRef
19.
Kaminski WE, Piehler A, Wenzel JJ (2006) ABC A-subfamily transporters: structure, function and disease. Biochim Biophys Acta 1762:510–524 (Epub 2006 Feb 28)PubMed
20.
Katagiri K, Matsuura S (1971) Antitumor activity of cytochalasin D. J Antibiot (Tokyo) 24:722–723
21.
Kelsell DP, Norgett EE, Unsworth H, Teh MT, Cullup T, Mein CA, Dopping-Hepenstal PJ, Dale BA, Tadini G, Fleckman P, Stephens KG, Sybert VP, Mallory SB, North BV, Witt DR, Sprecher E, Taylor AE, Ilchyshyn A, Kennedy CT, Goodyear H, Moss C, Paige D, Harper JI, Young BD, Leigh IM, Eady RA, O’Toole EA (2005) Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet 76:794–803 (Epub 2005 Mar 8)PubMedCrossRef
22.
Kim M, Yan Y, Kortum RL, Stoeger SM, Sgagias MK, Lee K, Lewis RE, Cowan KH (2005) Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity. Cancer Res 65:3986–3992PubMedCrossRef
23.
Kim YK, Kim HJ, Kwon CH, Kim JH, Woo JS, Jung JS, Kim JM (2005) Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol 25:374–382PubMedCrossRef
24.
Koo HM, Monks A, Mikheev A, Rubinstein LV, Gray-Goodrich M, McWilliams MJ, Alvord WG, Oie HK, Gazdar AF, Paull KD, Zarbl H, Vande Woude GF (1996) Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res 56:5211–5216PubMed
25.
Kornfeld K, Hom DB, Horvitz HR (1995) The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans. Cell 83:903–913PubMedCrossRef
26.
Kortum RL, Costanzo DL, Haferbier J, Schreiner SJ, Razidlo GL, Wu MH, Volle DJ, Mori T, Sakaue H, Chaika NV, Chaika OV, Lewis RE (2005) The molecular scaffold kinase suppressor of Ras 1 (KSR1) regulates adipogenesis. Mol Cell Biol 25:7592–7604PubMedCrossRef
27.
Kortum RL, Johnson HJ, Costanzo DL, Volle DJ, Razidlo GL, Fusello AM, Shaw AS, Lewis RE (2006) The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12-induced and replicative senescence. Mol Cell Biol 26:2202–2214PubMedCrossRef
28.
Kortum RL, Lewis RE (2004) The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol Cell Biol 24:4407–4416PubMedCrossRef
29.
Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL (2000) Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60:5887–5894PubMed
30.
Lefevre C, Audebert S, Jobard F, Bouadjar B, Lakhdar H, Boughdene-Stambouli O, Blanchet-Bardon C, Heilig R, Foglio M, Weissenbach J, Lathrop M, Prud’homme JF, Fischer J (2003) Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet 12:2369–2378 (Epub 2003 Jul 15)PubMedCrossRef
31.
Lozano J, Xing R, Cai Z, Jensen HL, Trempus C, Mark W, Cannon R, Kolesnick R (2003) Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. Cancer Res 63:4232–4238PubMed
32.
Matheny SA, Chen C, Kortum RL, Razidlo GL, Lewis RE, White MA (2004) Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature 427:256–260PubMedCrossRef
33.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2006) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 7:7
34.
Miyata Y (2005) Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 11:1131–1138PubMedCrossRef
35.
Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A et al (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757–766PubMedCrossRef
36.
Morrison DK (2001) KSR: a MAPK scaffold of the Ras pathway? J Cell Sci 114:1609–1612PubMed
37.
Moscow J, Schneider E, Sikic B, Morrow C, Cowan K (2006) Drug resistance and its clinical circumvention. In: Kufe D, Bast R, Hait W, Hong W, Pollock R, Weichselbaum R, Holland J, Frei E (eds) Cancer medicine, vol 7. BC Decker Inc, Hamilton, pp 630–647
38.
Moscow JA, Connolly T, Myers TG, Cheng CC, Paull K, Cowan KH (1997) Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines. Int J Cancer 72:184–190PubMedCrossRef
39.
Muller J, Ory S, Copeland T, Piwnica-Worms H, Morrison DK (2001) C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol Cell 8:983–993PubMedCrossRef
40.
Natarajan P, May JA, Sanderson HM, Zabe M, Spangenberg P, Heptinstall S (2000) Effects of cytochalasin H, a potent inhibitor of cytoskeletal reorganisation, on platelet function. Platelets 11:467–476PubMedCrossRef
41.
Nguyen A, Burack WR, Stock JL, Kortum R, Chaika OV, Afkarian M, Muller WJ, Murphy KM, Morrison DK, Lewis RE, McNeish J, Shaw AS (2002) Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol Cell Biol 22:3035–3045PubMedCrossRef
42.
Nguyen DT, Kebache S, Fazel A, Wong HN, Jenna S, Emadali A, Lee EH, Bergeron JJ, Kaufman RJ, Larose L, Chevet E (2004) Nck-dependent activation of extracellular signal-regulated kinase-1 and regulation of cell survival during endoplasmic reticulum stress. Mol Biol Cell 15:4248–4260 (Epub 2004 Jun 16)PubMedCrossRef
43.
Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088–1092PubMedCrossRef
44.
Persons DL, Yazlovitskaya EM, Cui W, Pelling JC (1999) Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5:1007–1014PubMed
45.
Persons DL, Yazlovitskaya EM, Pelling JC (2000) Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275:35778–35785PubMedCrossRef
46.
Razidlo GL, Kortum RL, Haferbier JL, Lewis RE (2004) Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. J Biol Chem 279:47808–47814 (Epub 2004 Sep 13)PubMedCrossRef
47.
Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113–1118PubMedCrossRef
48.
Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM (2001) Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19:2319–2333PubMed
49.
Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823PubMedCrossRef
50.
Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA (2004) JAK/STAT, Raf/MEK/ERK, PI3 K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189–218PubMedCrossRef
51.
Sundaram M, Han M (1995) The C. elegans ksr-1 gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. Cell 83:889–901PubMedCrossRef
52.
Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129–137PubMedCrossRef
53.
Szegezdi E, Fitzgerald U, Samali A (2003) Caspase-12 and ER-stress-mediated apoptosis: the story so far. Ann N Y Acad Sci 1010:186–194PubMedCrossRef
54.
Therrien M, Chang HC, Solomon NM, Karim FD, Wassarman DA, Rubin GM (1995) KSR, a novel protein kinase required for RAS signal transduction. Cell 83:879–888PubMedCrossRef
55.
Vicentini L, Mazzi P, Caveggion E, Continolo S, Fumagalli L, Lapinet-Vera JA, Lowell CA, Berton G (2002) Fgr deficiency results in defective eosinophil recruitment to the lung during allergic airway inflammation. J Immunol 168:6446–6454PubMed
56.
Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275:39435–39443PubMedCrossRef
57.
Wang X, Studzinski GP (2001) Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by “MEK-specific” inhibitors PD 098059 and U0126 in differentiating HL60 cells. Exp Cell Res 268:294–300PubMedCrossRef
58.
Wang X, Studzinski GP (2004) Kinase suppressor of RAS (KSR) amplifies the differentiation signal provided by low concentrations 1, 25-dihydroxyvitamin D3. J Cell Physiol 198:333–342PubMedCrossRef
59.
Wang X, Wang TT, White JH, Studzinski GP (2006) Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5′-flanking region. Oncogene. 25:7078–7085 (Epub 2006 May 29)PubMedCrossRef
60.
Wei SQ, Sui LH, Zheng JH, Zhang GM, Kao YL (2004) Role of ERK1/2 kinase in cisplatin-induced apoptosis in human ovarian carcinoma cells. Chin Med Sci J 19:125–129PubMed
61.
Wells JM, Cutler HG, Cole RJ (1976) Toxicity and plant growth regulator effects of cytochalasin H isolated from Phomopsis sp. Can J Microbiol 22:1137–1143PubMedCrossRef
62.
Xing H, Kornfeld K, Muslin AJ (1997) The protein kinase KSR interacts with 14–3-3 protein and Raf. Curr Biol 7:294–300PubMedCrossRef
63.
Xing HR, Cordon-Cardo C, Deng X, Tong W, Campodonico L, Fuks Z, Kolesnick R (2003) Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med 9:1266–1268 (Epub 2003 Sep 7)PubMedCrossRef
64.
Yahara I, Harada F, Sekita S, Yoshihira K, Natori S (1982) Correlation between effects of 24 different cytochalasins on cellular structures and cellular events and those on actin in vitro. J Cell Biol 92:69–78PubMedCrossRef
Metadata
Title
Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines
Authors
Scott M. Stoeger
Kenneth H. Cowan
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0794-7

Other articles of this Issue 5/2009

Cancer Chemotherapy and Pharmacology 5/2009 Go to the issue

Original Article

A model-based approach to the in vitro evaluation of anticancer activity

Original Article

Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival

Clinical Trial Report

Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial

Original Article

Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases

Original Article

The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population

Clinical Trial Report

A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits